STOCK TITAN

Agenus Inc. (AGEN) expands board, appoints Marco Tullio Marcucci as Class II director

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Agenus Inc. expanded its board of directors from six to seven members and appointed Marco Tullio Marcucci as a Class II director, effective August 5, 2026. He will serve until the 2029 annual meeting of stockholders and also join the Corporate Governance and Nominating Committee. Marcucci, age 55, is an attorney based in Rome with experience in commercial and civil law, tax and administrative litigation, wealth management, capital markets, venture capital, and cross-border transactions, including biotechnology and technology investments.

As a non-employee director, Marcucci will receive an $75,000 annual cash retainer, plus $7,500 annually for committee membership. He was granted an option to purchase 7,500 shares of common stock, vesting in three equal annual installments starting August 5, 2027, subject to continued board service. Agenus states there are no appointment arrangements, family relationships, or related-party transactions requiring disclosure.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Board size after change 7 directors Board increased from six to seven members on August 5, 2026
Director age 55 Age of Marco Tullio Marcucci at time of appointment
Annual director cash retainer $75,000 Annual cash retainer for non-employee director service
Committee retainer $7,500 Annual Corporate Governance and Nominating Committee membership retainer
Stock options granted 7,500 shares Option grant upon appointment on August 5, 2026
Director term end 2029 annual meeting Marcucci serves as Class II director until 2029 meeting and successor qualification
Class II director regulatory
"appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Corporate Governance and Nominating Committee regulatory
"Mr. Marcucci was also appointed to serve as a member of the Board’s Corporate Governance and Nominating Committee"
A corporate governance and nominating committee is a group of independent board members who set rules for how a company is run and choose or vet candidates for the board and senior leadership. Think of them as the company’s rulebook authors and hiring panel for its top oversight team; their choices and policies influence management accountability, risk oversight and investor confidence, so investors watch them for signs of strong leadership and transparency.
non-employee director compensation program financial
"compensated in accordance with the Company’s non-employee director compensation program"
equity incentive plan financial
"subject to the terms and conditions of the Company’s applicable equity incentive plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
indemnification agreement regulatory
"The Company has entered into the Company’s standard form of indemnification agreement with Mr. Marcucci"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

FAQ

What governance change did Agenus Inc. (AGEN) report in this 8-K?

Agenus Inc. expanded its board from six to seven directors and appointed attorney Marco Tullio Marcucci as a Class II director and member of the Corporate Governance and Nominating Committee.

Who is Marco Tullio Marcucci, the new director at Agenus Inc. (AGEN)?

Marco Tullio Marcucci is a 55-year-old attorney based in Rome with experience in commercial and civil law, litigation, wealth management, capital markets, venture capital, and cross-border transactions, including evaluating biotechnology and technology investments.

How will Agenus Inc. (AGEN) compensate new director Marco Tullio Marcucci?

Marcucci will receive an annual cash retainer of $75,000 plus $7,500 for Corporate Governance and Nominating Committee service. He also received an option to purchase 7,500 shares of Agenus common stock, vesting over three years.

What are the terms of Marco Tullio Marcucci’s stock option from Agenus Inc. (AGEN)?

On August 5, 2026, Marcucci received an option for 7,500 shares of common stock. The option vests in three equal annual installments beginning August 5, 2027, contingent on his continued board service, with no vesting before that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false000109897200010989722026-08-052026-08-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2026

 

 

AGENUS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-29089

06-1562417

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3 Forbes Road

 

Lexington, Massachusetts

 

02421

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 781 674-4400

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value per share

 

AGEN

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 5, 2026, the board of directors (the “Board”) of Agenus Inc., a Delaware corporation (the “Company”), increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director, to serve until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified, effective immediately. Mr. Marcucci was also appointed to serve as a member of the Board’s Corporate Governance and Nominating Committee. Following Mr. Marcucci’s appointment, the Board consists of seven (7) directors, including Brian Corvese and Timothy R. Wright, serving as Class I directors; Garo Armen, Jennifer Buell and Marco Tullio Marcucci, serving as Class II directors; and Susan Hirsch and Thomas Harrison, serving as Class III directors.

 

Mr. Marcucci, age 55, is an attorney based in Rome, Italy. Since 2003, he has practiced at Studio Legale Pecora Marcucci, where he advises individuals and companies on commercial and civil law, administrative and tax litigation, wealth management, capital markets investments, venture capital activities, and domestic and cross-border agreements. He previously served as in-house legal counsel at H3G S.p.A. in Rome and held earlier legal roles involving corporate law, competition law and transnational joint ventures. Mr. Marcucci has been admitted to the Bar Association of Rome since 2002 and to the Special Bar Association of the Supreme Court and High Courts since 2018. We believe Mr. Marcucci is qualified to serve on the Board because of his extensive legal, capital markets, investment, venture capital and cross-border transactional experience, including experience evaluating investments in biotechnology and technology companies.

 

Mr. Marcucci will be compensated in accordance with the Company’s non-employee director compensation program, as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2026. Mr. Marcucci will receive an annual cash retainer of $75,000 and an annual Corporate Governance and Nominating Committee membership retainer of $7,500. In connection with his appointment, on August 5, 2026, Mr. Marcucci was granted an option to purchase 7,500 shares of the Company’s common stock. The option will vest in three equal annual installments commencing on the first anniversary of the date of grant, in each case subject to Mr. Marcucci’s continued service on the Board through the applicable vesting date. No portion of the option will vest before August 5, 2027. The award is subject to the terms and conditions of the Company’s applicable equity incentive plan and the applicable award agreement. The Company has entered into the Company’s standard form of indemnification agreement with Mr. Marcucci.

 

There is no arrangement or understanding pursuant to which Mr. Marcucci was appointed to the Board. There are no family relationships between Mr. Marcucci and any director or executive officer of the Company as defined in Item 401(d) of Regulation S-K. Mr. Marcucci does not have any direct or indirect material interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Agenus Inc.

 

 

 

 

Date:

August 11, 2026

By:

/s/ Garo H. Armen

 

 

 

Garo H. Armen, Chairman and CEO

 


Filing Exhibits & Attachments

1 document